Abstract
Several population groups display an increased risk of severe disease and mortality following SARS-CoV-2 infection. These include those who are immunocompromised (IC), have a cancer diagnosis, human immunodeficiency virus (HIV) infection or chronic inflammatory disease including autoimmune disease, primary immunodeficiencies, and those with kidney or liver disease. As such, improved understanding of the course of COVID-19 disease, as well as the efficacy, safety, and benefit-risk profiles of COVID-19 vaccines in these vulnerable groups is paramount in order to inform health policy makers and identify evidence-based vaccination strategies. In this review, we seek to summarize current data, including recommendations by national health authorities, on the impact and benefit-risk profiles of COVID-19 vaccination in these populations. Moving forward, although significant efforts have been made to elucidate and characterize COVID-19 disease course and vaccine responses in these groups, further larger-scale and longer-term evaluation will be instrumental to help further guide management and vaccination strategies, particularly given concerns about waning of vaccine-induced immunity and the recent surge of transmission with SARS-CoV-2 variants of concern.
Keywords: COVID-19; Immunocompromised; Kidney disease; Liver disease; Oncology; Special populations; Vaccination.
【저자키워드】 COVID-19, vaccination, Immunocompromised, Kidney disease, Liver disease, Special populations, oncology, 【초록키워드】 HIV, Efficacy, COVID-19 vaccine, Mortality, SARS-COV-2 infection, SARS-CoV-2 variant, Infection, Health policy, Transmission, COVID-19 disease, kidney, Autoimmune disease, COVID-19 vaccines, Health, COVID-19 vaccination, SARS-CoV-2 variants, vaccine response, management, Vaccination strategies, Immunocompromised, Kidney disease, group, Human immunodeficiency virus, severe disease, Liver disease, Vaccine-induced immunity, vaccine responses, population groups, oncology, increased risk, immunodeficiency virus, help, effort, national health authorities, chronic inflammatory disease, cancer diagnosis, recommendation, populations, kidney or liver disease, benefit-risk profile, COVID-19 disease course, Course, identify, include, groups, 【제목키워드】 group,